Male hypogonadism
- PMID: 24119423
- DOI: 10.1016/S0140-6736(13)61126-5
Male hypogonadism
Abstract
Male hypogonadism is a clinical syndrome that results from failure to produce physiological concentrations of testosterone, normal amounts of sperm, or both. Hypogonadism may arise from testicular disease (primary hypogonadism) or dysfunction of the hypothalamic-pituitary unit (secondary hypogonadism). Clinical presentations vary dependent on the time of onset of androgen deficiency, whether the defect is in testosterone production or spermatogenesis, associated genetic factors, or history of androgen therapy. The clinical diagnosis of hypogonadism is made on the basis of signs and symptoms consistent with androgen deficiency and low morning testosterone concentrations in serum on multiple occasions. Several testosterone-replacement therapies are approved for treatment and should be selected according to the patient's preference, cost, availability, and formulation-specific properties. Contraindications to testosterone-replacement therapy include prostate and breast cancers, uncontrolled congestive heart failure, severe lower-urinary-tract symptoms, and erythrocytosis. Treatment should be monitored for benefits and adverse effects.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Similar articles
-
Diagnosis and treatment of hypogonadism in men.Best Pract Res Clin Endocrinol Metab. 2011 Apr;25(2):251-70. doi: 10.1016/j.beem.2010.12.002. Best Pract Res Clin Endocrinol Metab. 2011. PMID: 21397197 Review.
-
Testosterone treatment in elderly men.Adv Ther. 2009 Jan;26(1):25-39. doi: 10.1007/s12325-008-0137-4. Epub 2009 Jan 27. Adv Ther. 2009. PMID: 19198768 Review.
-
[Testosterone substitution in patients with hypogonadism].Arch Esp Urol. 2002 Sep;55(7):827-38. Arch Esp Urol. 2002. PMID: 12380312 Review. Spanish.
-
Testosterone deficiency syndrome: benefits, risks, and realities associated with testosterone replacement therapy.Can J Urol. 2016 Feb;23(Suppl 1):20-30. Can J Urol. 2016. PMID: 26924592
-
An update on male hypogonadism therapy.Expert Opin Pharmacother. 2014 Jun;15(9):1247-64. doi: 10.1517/14656566.2014.913022. Epub 2014 Apr 23. Expert Opin Pharmacother. 2014. PMID: 24758365 Free PMC article.
Cited by
-
The -KTS isoform of Wt1 induces the transformation of Leydig cells into granulosa-like cells.Cell Discov. 2024 Nov 12;10(1):113. doi: 10.1038/s41421-024-00732-6. Cell Discov. 2024. PMID: 39528444 Free PMC article. No abstract available.
-
Role of intestinal testosterone-degrading bacteria and 3/17β-HSD in the pathogenesis of testosterone deficiency-induced hyperlipidemia in males.NPJ Biofilms Microbiomes. 2024 Nov 9;10(1):123. doi: 10.1038/s41522-024-00599-1. NPJ Biofilms Microbiomes. 2024. PMID: 39521773 Free PMC article.
-
Safety and efficacy of enclomiphene and clomiphene for hypogonadal men.Transl Androl Urol. 2024 Sep 30;13(9):1984-1990. doi: 10.21037/tau-24-238. Epub 2024 Sep 24. Transl Androl Urol. 2024. PMID: 39434750 Free PMC article.
-
Clomiphene Citrate Treatment as an Alternative Therapeutic Approach for Male Hypogonadism: Mechanisms and Clinical Implications.Pharmaceuticals (Basel). 2024 Sep 18;17(9):1233. doi: 10.3390/ph17091233. Pharmaceuticals (Basel). 2024. PMID: 39338395 Free PMC article. Review.
-
Hormone Regulation in Testicular Development and Function.Int J Mol Sci. 2024 May 26;25(11):5805. doi: 10.3390/ijms25115805. Int J Mol Sci. 2024. PMID: 38891991 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
